|
| Primary information |
|---|
| ID | 10870 |
| Therapeutic ID | Th1230 |
| Protein Name | Human Varicella-Zoster Immune Globulin |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Human Varicella-Zoster Immunoglobulin has a half-life of about 18-24 days following intravenous administration and 24-30 days following intramuscular administration. |
| Description | Human Varicella-Zoster Immune Globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). |
| Indication/Disease | Indicated for reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals after exposure |
| Pharmacodynamics | Provides passive immunization for nonimmune individuals exposed to varicella zoster virus, thereby reducing the severity of varicella infections |
| Mechanism of Action | NA |
| Toxicity | Since the drug was prepared from human plasma pool, it may contain other infectious agents such as viruses and Creutzfeldt-Jakob disease (vCJD) agent. Hypersensitivity reactions such as allergic or anaphylactic reactions may occur. More common adverse effects include pain at injection site, headache, and rash. Rare adverse effects from immune globulin intravenous therapy include thrombotic events, renal dysfunction and acute renal failure, and noncardiogenic pulmonary edema. An LD50 was not determined, as the maximal dose used did not kill any experimental animals. |
| Metabolism | Immune globulins are metabolized in the reticuloendothelial system. |
| Absorption | Intravenous administration of varicella zoster antibodies tends to persist for 6 weeks or longer. Following intramuscular administration of varicella immune globulin products, varicella antibodies are detectable within 2-3 days. The peak levels of varicella antibodies is expected to occur within 3-7 days of VariZIG administration. |
| Following intravenous administration of varicella zoster VZIG, anti-varicella zoster antibodies are expected to be quickly distributed between plasma and extravascular spaces with complete and immediate bioavailability. Intramuscular administration achieves nearly 100% bioavailability. |
| Clearance | NA |
| Categories | Antibody |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | The passive transfer of antibodies with immune globulin administration may impair the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella |
| Target | varicella zoster virus |
| Brand Name | VARIZIG |
| Company | NA |
| Brand Description | NA |
| Prescribed For | It is indicated for post-exposure prophylaxis of varicella in high risk individuals. |
| Chemical Name | NA |
| Formulation | It is available in a single-use vial of 125 IU. Each 125 IU vial of VARIZIG contains less than 156 milligrams of total protein, mostly human immune globulin G (IgG). VARIZIG contains no preservative |
| Physical Appearance | lyophilized powder for solution |
| Route of Administration | Intramuscular |
| Recommended Dosage | Depending on patient size, divide the IM dose and administer in 2 or more injection sites; not to exceed 3 mL/injection site |
| Contraindication | Hypersensitivity to human immunoglobulins |
| Side Effects | The most common adverse drug reactions (reported by ≥ 1% of subjects) observed in clinical trials for all subjects and patients (n=601) are the following:injection site pain (3%),headache (2%),rash (including terms pruritus, rash, rash erythematous, rash vesicular and urticaria) (1%),fatigue (1%),chills (1%),nausea (1%) |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |